Skip to main content

On April 13th, 2023, the UCB’s Global Corporate Website released a press statementJames F. Howard, Jr., MD regarding the RAISE clinical trial of zilucoplan – one of two drugs being reviewed for the treatment of myasthenia gravis. The trial was led by James Howard, MD, who is a neurology professor at the UNC School of Medicine.

Read more on the School of Medicine’s Newsroom: Rozanolixizumab, Zilucoplan Phase 3 Generalized Myasthenia Gravis Study Results Published in The Lancet Neurology

Also view The Lancet Neurology article: Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study